Clinical Use of Irinotecan: Current Status and Future Considerations

Area of Science:

• Pharmacology
• Oncology
• Drug Development

Background:

• Irinotecan (CPT-11) is a semisynthetic derivative of camptothecin.
• It is a water-soluble chemotherapy agent.
• Irinotecan is approved in the United States for specific cancer treatments.

Purpose of the Study:

• To review the approved clinical applications of Irinotecan.
• To discuss the toxicity profile and management strategies for Irinotecan.
• To explore ongoing clinical investigations into potential new uses of Irinotecan.

Main Methods:

• Literature review of clinical investigations.
• Analysis of approved drug indications.
• Examination of toxicity data and management protocols.

Main Results:

• Irinotecan is effective for fluorouracil-refractory colorectal cancer.
• Key toxicities include diarrhea and neutropenia, with established management guidelines.
• Ongoing trials are investigating Irinotecan in various other cancers and treatment combinations.

Conclusions:

• Irinotecan is a valuable therapeutic agent in oncology.
• Effective management of its toxicities is crucial for patient care.
• Further research holds promise for expanding its clinical utility.